{
    "nctId": "NCT01149356",
    "briefTitle": "RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Incidence of treatment emergent adverse events (TEAEs) based on CTCAE version 3 grade",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of breast cancer\n\n  * Locally advanced or metastatic disease for which curative measures are not effective\n\n    * Relapsed disease with (or within 6 months of discontinuation of) an adjuvant nonsteroidal aromatase inhibitor or tamoxifen\n    * Progressive disease during treatment with first- or second-line hormonal therapy that could include a nonsteroidal aromatase inhibitor, tamoxifen, or fulvestrant\n  * Recurrent disease\n\n    * No locally recurrent resectable disease\n  * Histologically confirmed estrogen receptor-positive (ER+) by IHC\n\n    * Must have \u2265 5% strong staining for ER+ or \u2265 10% weak staining\n* Measurable disease defined as \u2265 1 lesion that can be accurately measured in \u2265 1 dimension (longest diameter to be recorded) as \u2265 20 mm by conventional techniques OR as \u2265 10 mm by spiral CT scan\n* No HER2/neu-positive disease\n* No known brain metastases\n* Pre- or postmenopausal status\n* ECOG performance status 0-1\n* Life expectancy \u2265 6 months\n* WBC \u2265 3,500/mm\\^3\n* ANC \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9 g/dL\n* Total bilirubin \u2264 2 mg/dL\n* AST and ALT \u2264 2.5 times upper limit of normal\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* Able to swallow and retain oral medication\n* Negative pregnancy test\n* Not pregnant or nursing\n* Fertile patients must use effective contraception during and for \u2265 12 months after completion of study therapy\n* More than 5 years since other invasive cancer except basal or squamous cell cancer of the skin or cervical carcinoma in situ\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or other agents used in the study\n* No history of torsades de pointes\n* No malabsorption syndrome or other condition that would interfere with intestinal absorption (e.g., ulcerative colitis)\n* Not serologically positive for hepatitis B or C, have a history of liver disease, other forms of hepatitis, or cirrhosis\n* No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia\n* No uncontrolled intercurrent illness including, but not limited to, any of the following:\n\n  * Ongoing or active infection requiring parenteral antibiotics\n  * Impairment of lung function (e.g., chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)\n  * Symptomatic congestive heart failure (NYHA class III-IV heart disease)\n  * Unstable angina pectoris, angioplasty, stenting, and or myocardial infarction within the past 6 months\n  * Uncontrolled hypertension (systolic BP \\> 180 mm Hg or diastolic BP \\> 100 mm Hg on 2 consecutive measurements separated by a 1-week period) despite adequate medical support\n  * Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, torsades de pointes, ventricular tachycardia that is symptomatic, or requiring treatment)\n  * A requirement for antiarrthymics or other medications known to prolong QTC\n  * Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)\n  * Psychiatric illness and/or social situations that would limit compliance with study requirements\n* No baseline QTcF \\> 450 msec (male) or \\> 470 msec (female)\n* See Disease Characteristics\n* Fully recovered from all previous adverse events\n* No prior exemestane for metastatic or recurrent breast cancer, or within the past 6 months in the adjuvant setting\n* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)\n* At least 2 weeks since prior radiotherapy\n* At least 2 weeks since prior and no other concurrent investigational agents\n* No prior exposure to \u03b3-secretase inhibitors\n* No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin\u00ae)\n* No other concurrent CYP3A4 substrates, inducers, or inhibitors\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent anticancer agents or therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, or biologic therapy\n* No concurrent medications or food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including ketoconazole and grapefruit juice\n* No concurrent antiarrhythmics or other medications known to prolong QTc",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}